المصدر: A Phase 1b/2a Multi-Center, Dose Escalation and Reference Regimen-Controlled, Multi-Cohort Study to Determine the Safety and Efficacy of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy in Patients With Anti-PD-1-Resistant Locally Advanced or Metastatic Cancers

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06362369Test

المصدر: Pilot Single-Arm, Pragmatic Trial of In-Home Versus In-Clinic Subcutaneous Nivolumab Administration Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06265285Test

Other URLs: https://www.mayo.edu/research/clinical-trialsTest

المصدر: A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06242470Test

المؤلفون: National Cancer Institute (NCI)

المصدر: Maximizing Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06075524Test

Other URLs: https://www.mayo.edu/research/clinical-trialsTest

المصدر: A Feasibility Multicenter Phase I Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06066138Test

Other URLs: https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_001559-C.htmlTest

المصدر: A Prospective, Observational Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06028724Test

المؤلفون: National Cancer Institute (NCI)

المساهمون: Joseph Tuscano, Principal Investigator

المصدر: Single Arm Study to Assess the Immune Effects of Fermented Wheat Germ (FWG) Nutritional Supplementation in Patients With Advanced Malignancies Being Treated With Standard of Care Checkpoint Inhibitor-Based Therapy

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05967533Test

المصدر: Phase 1/2 Open Label, Safety and Preliminary Efficacy Study of a Live Biotherapeutic Product (CJRB-101) in Combination With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05877430Test

المؤلفون: Regeneron Pharmaceuticals

المصدر: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (Anti VISTA) as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05864144Test

المصدر: A Phase Ib/II Open Label, Multi-arm, Parallel Cohort Dose Finding and Expansion Study to Assess the Safety, Pharmacokinetics and Efficacy of NUC-3373, a Nucleotide Analogue, Given in Combination With Standard Approved Agents in Patients With Advanced Solid Tumours

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05714553Test